MX369968B - Procedimiento para elaborar la forma cristalina a de lenalidomida. - Google Patents

Procedimiento para elaborar la forma cristalina a de lenalidomida.

Info

Publication number
MX369968B
MX369968B MX2017002225A MX2017002225A MX369968B MX 369968 B MX369968 B MX 369968B MX 2017002225 A MX2017002225 A MX 2017002225A MX 2017002225 A MX2017002225 A MX 2017002225A MX 369968 B MX369968 B MX 369968B
Authority
MX
Mexico
Prior art keywords
lenalidomide
making crystalline
crystalline form
dimethylacetamide
dimethylformamide
Prior art date
Application number
MX2017002225A
Other languages
English (en)
Other versions
MX2017002225A (es
Inventor
Castulik Jakub
Vyklicky Libor
Jelinek Zdenek
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of MX2017002225A publication Critical patent/MX2017002225A/es
Publication of MX369968B publication Critical patent/MX369968B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con un procedimiento para elaborar la forma A cristalina de lenalidomida de la fórmula (1), caracterizada por un patrón de difracción de polvo XRPD que comprende los picos en aproximadamente 7.89, 4.35, 14.83, 15.81, 16.23, 20.12, 23.78, 24.09, 25.96 grados 2 theta, cuando se miden con la radiación CuKa1 (? = 1.54060 ?), el procedimiento comprende: 1. reducción de 3-(4-nitro-1-oxo-1,3-dihidro-2H-isoindo l-2-iI)-2,6-piperidinadiona de la fórmula (2) con un agente reductor en un solvente mezclado que comprende una mezcla de alcohol alifático de C1-C3 y N,N-dimetilformamida o N,N-dimetilacetamida, en donde el contenido de N,N-dimetilformamida o N,N-dimetilacetamida en el solvente mezclado está entre 20 y 40 % (v/v), 2; aislamiento de la forma de lenalidomida.
MX2017002225A 2014-08-19 2015-08-14 Procedimiento para elaborar la forma cristalina a de lenalidomida. MX369968B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2014067637 2014-08-19
PCT/EP2015/068774 WO2016026785A1 (en) 2014-08-19 2015-08-14 Process for making crystalline form a of lenalidomide

Publications (2)

Publication Number Publication Date
MX2017002225A MX2017002225A (es) 2017-05-22
MX369968B true MX369968B (es) 2019-11-27

Family

ID=53835469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002225A MX369968B (es) 2014-08-19 2015-08-14 Procedimiento para elaborar la forma cristalina a de lenalidomida.

Country Status (5)

Country Link
EP (1) EP3183244B1 (es)
KR (1) KR102516638B1 (es)
ES (1) ES2733813T3 (es)
MX (1) MX369968B (es)
WO (1) WO2016026785A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658935A (zh) * 2017-03-27 2018-10-16 天津大学 来那度胺新晶型、其制备方法及其医药用途
EP3687987A4 (en) * 2017-09-27 2021-03-24 Biocon Limited CRYSTALLINE FORMS OF LENALIDOMIDE
WO2019227968A1 (zh) * 2018-06-01 2019-12-05 上海博志研新药物技术有限公司 一种来那度胺的制备方法
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114601A2 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
JP5727944B2 (ja) * 2009-03-02 2015-06-03 ジェネリクス・［ユーケー］・リミテッド 改良プロセス
CA2773012A1 (en) * 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
LV14985B (lv) * 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process

Also Published As

Publication number Publication date
KR20170042765A (ko) 2017-04-19
EP3183244B1 (en) 2019-04-10
EP3183244A1 (en) 2017-06-28
KR102516638B1 (ko) 2023-04-03
WO2016026785A1 (en) 2016-02-25
MX2017002225A (es) 2017-05-22
ES2733813T3 (es) 2019-12-03

Similar Documents

Publication Publication Date Title
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX2018003280A (es) Proceso de compuesto antifungico.
MY196328A (en) New (Hetero)Aryl-Substituted-Piperidinyl Derivatives, A Process For Their Preparation And Pharmaceutical Compositions Containing Them
PH12015502615A1 (en) Chemical compounds
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
NZ711192A (en) Process for making benzoxazepin compounds
MX2017002225A (es) Procedimiento para elaborar la forma cristalina a de lenalidomida.
EP3795578A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
MX364479B (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
PH12015502486A1 (en) N-(2-fluoro-2-phenethyl)carboxamides as nematicides and endoparasiticides
MX2016005223A (es) Tinturas dispersas, su preparacion y su uso.
IN2014CH00304A (es)
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2015008624A (es) PROCESO PARA PREPARAR 6A, 14A-ETENOMORFINANOS 7ß SUSTITUIDOS Y 6A, 14A-ETANOMORFINANOS 7ß-SUSTITUIDOS.
MX2015012350A (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4.
RU2013140117A (ru) Способ получения модифицированной серы
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2018009943A (es) Proceso para la fabricacion de derivados de 3-piperazin-1-il-propi lamina.

Legal Events

Date Code Title Description
FG Grant or registration